Karyopharm Q2 net loss $67M; cash runway only to Sept 2026, sNDA on track

Karyopharm Therapeutics Inc.

Q2 2026 total revenue $33.4M (vs $37.9M YoY); U.S. XPOVIO net product revenue $30.8M (vs $29.7M).
Net loss $67.0M ($2.32/share) vs $37.3M loss ($4.32/share) in Q2 2025; operating loss $22.5M.
Cash $65.4M at June 30; expects funding only into Sept 2026; $15.8M term loan payment due Sept 10, 2026 may trigger default.
Planned August sNDA for selinexor+ruxolitinib in myelofibrosis under Accelerated Approval; FDA feedback supports SVR35 as surrogate.
Phase 3 XPORT-EC-042 endometrial trial missed primary endpoint (PFS); median PFS 12.75 vs 7.43 months, HR 0.76, p=0.0791.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.